Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Eventide Healthcare & Life Sciences Fund CLASS I SHARES (ETIHX)

19.70
Net Asset Value
+1.13%
1 Day
-17.75%
Year-to-Date
Overall Morningstar Rating
Health
Style or Category
No Load
Sales Expenses
1.32%
Expense Ratio
High
Morningstar Risk Rating™
Investment Objective The investment seeks to provide long-term capital appreciation. Under normal market conditions, the fund will invest at least 80% of its net assets (plus borrowings for investment purposes) in equity and equity-related securities of companies in the healthcare and life sciences sectors, including common stock, options, preferred stock and convertible debt. It is non-diversified.

Performance

1 month+1.44% 3 years+17.86%
3 months+15.07% 5 years--
1 year-22.77% Since inception+21.76%
Data through --

Peer Comparisonvs. Health

 ETIHXCategory
Performance 5-yr return--+16.17%
Expense ratio1.32%1.34%
Risk 5 year sharpe ratio--1.01
Net assets$314.9M$3.2B
Average market cap$1.7B$27.9B
Average P/E--24.4
Portfolio turnover26%26%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyEventide Funds
Fund manager & tenureFinny Kuruvilla / 3 Years
Minimal initial investment$100,000.00
Minimum IRA investment$100,000.00

Holdings

U.S. stock85.41%
Cash8.06%
International stock4.16%
Other1.64%
Fixed income0.72%
Top 5 Sectors
Portfolio weighting
Business service --
Consumer goods --
Consumer service --
Energy --
Financial service --
Top 10 Holdings
Portfolio weighting
FPRX Five Prime Therapeutics Inc4.46%
COLL Collegium Pharmaceutical Inc3.91%
RARE Ultragenyx Pharmaceutical Inc2.39%
LOXO Loxo Oncology Inc2.34%
TSRO TESARO Inc2.30%
PTLA Portola Pharmaceuticals Inc2.30%
KITE Kite Pharma Inc2.23%
DBVT DBV Technologies SA2.21%
CELG Celgene2.20%
SGEN Seattle Genetics Inc2.14%

Partner Offers